R 115777

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461004

CAS#: 192185-68-5

Description: R 115777 is a farnesyl transferase inhibitor.

Chemical Structure

img
R 115777
CAS# 192185-68-5
Instruction

Theoretical Analysis

MedKoo Cat#: 461004
Name: R 115777
CAS#: 192185-68-5
Chemical Formula: C27H22Cl2N4O
Exact Mass: 488.12
Molecular Weight: 489.400
Elemental Analysis: C, 66.26; H, 4.53; Cl, 14.49; N, 11.45; O, 3.27

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: R 115777; R-115777; R115777

IUPAC/Chemical Name: 2(1H)-Quinolinone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl-

InChi Key: PLHJCIYEEKOWNM-UHFFFAOYSA-N

InChi Code: InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3

SMILES Code: O=C1N(C)C2=C(C=C(C(C3=CC=C(Cl)C=C3)(N)C4=CN=CN4C)C=C2)C(C5=CC=CC(Cl)=C5)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 489.40 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Jabbour E, Kantarjian H, Cortes J. Clinical activity of tipifarnib in hematologic malignancies. Expert Opin Investig Drugs. 2007 Mar;16(3):381-92. Review. PubMed PMID: 17302532.

2: Lavelle F. American Association for Cancer Research 1999: 10-14 April, Philadelphia, Pennsylvania. Expert Opin Investig Drugs. 1999 Jun;8(6):903-9. PubMed PMID: 15992139.

3: Lavelle F. American Association for Cancer Research 1998: promises and prospects for the next century. Expert Opin Investig Drugs. 1998 Jun;7(6):1015-21. PubMed PMID: 15992013.

4: Morgan MA, Ganser A, Reuter CW. Therapeutic efficacy of prenylation inhibitors in the treatment of myeloid leukemia. Leukemia. 2003 Aug;17(8):1482-98. Review. PubMed PMID: 12886235.

5: R-115777. Drug News Perspect. 2000 Dec;13(10):621. PubMed PMID: 12879132.

6: Dempke WC. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas. Anticancer Res. 2003 Mar-Apr;23(2A):813-8. Review. PubMed PMID: 12820305.

7: Haller DG. Future directions in the treatment of pancreatic cancer. Semin Oncol. 2002 Dec;29(6 Suppl 20):31-9. Review. PubMed PMID: 12577231.

8: Singh SB, Lingham RB. Current progress on farnesyl protein transferase inhibitors. Curr Opin Drug Discov Devel. 2002 Mar;5(2):225-44. Review. PubMed PMID: 11926129.